间变性甲状腺癌的免疫治疗
Immunotherapy in anaplastic thyroid cancer.
作者信息
Ma Maoguang, Lin Bo, Wang Mingdian, Liang Xiaoli, Su Lei, Okose Okenwa, Lv Weiming, Li Jie
机构信息
Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Sun Yat-sen University Guangzhou, China.
State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Guangzhou, China.
出版信息
Am J Transl Res. 2020 Mar 15;12(3):974-988. eCollection 2020.
Abstract
Anaplastic thyroid cancer (ATC) is one of the worst human malignancies, with an associated median survival of only 5 months. It is resistant to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression. Cancer immunotherapy has emerged over the past few decades as a transformative approach to treating a wide variety of cancers. However, immunotherapy for ATC is still in the experimental stage. This review will cover several strategies of immunotherapy and discuss the possible application of these strategies in the treatment of ATC (such as targeted therapy for tumor-associated macrophages, cancer vaccines, adoptive immunotherapy, monoclonal antibodies and immune checkpoint blockade) with the hope of improving the prognosis of ATC in the future.
摘要
间变性甲状腺癌（ATC）是最严重的人类恶性肿瘤之一，其相关的中位生存期仅为5个月。它对包括放射性碘和促甲状腺激素抑制在内的传统甲状腺癌治疗具有抗性。在过去几十年中，癌症免疫疗法已成为治疗多种癌症的变革性方法。然而，ATC的免疫疗法仍处于实验阶段。本综述将涵盖几种免疫疗法策略，并讨论这些策略在ATC治疗中的可能应用（如针对肿瘤相关巨噬细胞的靶向治疗、癌症疫苗、过继性免疫疗法、单克隆抗体和免疫检查点阻断），以期未来改善ATC的预后。
相似文献
1
Immunotherapy in anaplastic thyroid cancer.间变性甲状腺癌的免疫治疗
Am J Transl Res. 2020 Mar 15;12(3):974-988. eCollection 2020.
2
Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?免疫疗法还是靶向疗法：间变性甲状腺癌未来的治疗方向是什么？
Front Oncol. 2023 Mar 17;13:1103147. doi: 10.3389/fonc.2023.1103147. eCollection 2023.
3
Immunotherapy for anaplastic thyroid carcinoma: the present and future.间变性甲状腺癌的免疫治疗：现状与未来。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Dec 25;50(6):675-684. doi: 10.3724/zdxbyxb-2021-0273.
4
Research progress of immunotherapy against anaplastic thyroid cancer.间变性甲状腺癌免疫治疗的研究进展
Front Oncol. 2024 Mar 26;14:1365055. doi: 10.3389/fonc.2024.1365055. eCollection 2024.
5
Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.乳腺癌免疫疗法：现代检查点阻断策略与疫苗概述
Curr Probl Cancer. 2016 Mar-Aug;40(2-4):151-162. doi: 10.1016/j.currproblcancer.2016.09.009. Epub 2016 Sep 26.
6
Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.晚期间变性甲状腺癌经全身治疗后生存率提高。
Laryngoscope. 2025 Jan;135(1):478-484. doi: 10.1002/lary.31712. Epub 2024 Aug 20.
7
TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages: An Emerging Immunotherapeutic Target.TIM3在间变性甲状腺癌浸润巨噬细胞中的表达：一个新兴的免疫治疗靶点。
Biology (Basel). 2022 Nov 3;11(11):1609. doi: 10.3390/biology11111609.
8
Harnessing Immunity to Treat Advanced Thyroid Cancer.利用免疫疗法治疗晚期甲状腺癌。
Vaccines (Basel). 2023 Dec 30;12(1):45. doi: 10.3390/vaccines12010045.
9
Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.人未分化甲状腺癌细胞对 NK 细胞介导的裂解敏感，通过 ULBP2/5/6 趋化 NK 细胞。
Clin Cancer Res. 2014 Nov 15;20(22):5733-44. doi: 10.1158/1078-0432.CCR-14-0291. Epub 2014 Sep 11.
10
Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.表达钠碘转运体的麻疹病毒在碘非亲和性间变性甲状腺癌中的临床前疗效：一种允许无创成像和放射性碘治疗的新型治疗剂。
Cancer Gene Ther. 2012 Sep;19(9):659-65. doi: 10.1038/cgt.2012.47. Epub 2012 Jul 13.
引用本文的文献
1
Triumph Over Butchery: Guest Editorial for Indian Journal of Surgical Oncology.战胜屠杀：《印度外科肿瘤学杂志》客座社论
Indian J Surg Oncol. 2025 Feb;16(1):5-7. doi: 10.1007/s13193-024-02150-2. Epub 2024 Dec 13.
2
Modern Therapeutic Approaches in Anaplastic Thyroid Cancer: A Meta-Analytic Review of Randomised and Single Arm Studies on Efficacy and Survival.间变性甲状腺癌的现代治疗方法：关于疗效和生存的随机及单臂研究的荟萃分析综述
Cancers (Basel). 2025 Feb 24;17(5):777. doi: 10.3390/cancers17050777.
3
PD-L1 Expression Varies in Thyroid Cancer Types and Is Associated with Decreased Progression Free Survival (PFS) in Patients with Anaplastic Thyroid Cancer.程序性死亡受体配体1（PD-L1）的表达在不同类型的甲状腺癌中有所不同，并且与间变性甲状腺癌患者无进展生存期（PFS）缩短相关。
Cancers (Basel). 2024 Oct 28;16(21):3632. doi: 10.3390/cancers16213632.
4
Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.基于文献计量学和临床试验的甲状腺癌免疫治疗现状与未来
Discov Oncol. 2024 Feb 25;15(1):50. doi: 10.1007/s12672-024-00904-6.
5
Harnessing Immunity to Treat Advanced Thyroid Cancer.利用免疫疗法治疗晚期甲状腺癌。
Vaccines (Basel). 2023 Dec 30;12(1):45. doi: 10.3390/vaccines12010045.
6
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.肿瘤相关巨噬细胞作为甲状腺癌潜在的治疗靶点。
Cancer Immunol Immunother. 2023 Dec;72(12):3895-3917. doi: 10.1007/s00262-023-03549-6. Epub 2023 Oct 5.
7
Increased SEMA6B expression as a potential prognostic and immune cell infiltration biomarker in thyroid cancer patients.SEMA6B 表达升高可作为甲状腺癌患者潜在的预后和免疫细胞浸润标志物。
Aging (Albany NY). 2023 May 5;15(9):3572-3585. doi: 10.18632/aging.204691.
8
Identification of novel immune-related molecular subtypes and a prognosis model to predict thyroid cancer prognosis and drug resistance.新型免疫相关分子亚型的鉴定及预测甲状腺癌预后和耐药性的预后模型
Front Pharmacol. 2023 Mar 30;14:1130399. doi: 10.3389/fphar.2023.1130399. eCollection 2023.
9
Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?免疫疗法还是靶向疗法：间变性甲状腺癌未来的治疗方向是什么？
Front Oncol. 2023 Mar 17;13:1103147. doi: 10.3389/fonc.2023.1103147. eCollection 2023.
10
Constructing a thyroid cancer prognostic risk model based on CD8 T cell associated genes.基于CD8 T细胞相关基因构建甲状腺癌预后风险模型。
Cent Eur J Immunol. 2022;47(3):234-245. doi: 10.5114/ceji.2022.119171. Epub 2022 Nov 16.
本文引用的文献
1
Pembrolizumab for anaplastic thyroid cancer: a case study.帕博利珠单抗治疗间变性甲状腺癌：1 例病例报告。
Cancer Immunol Immunother. 2019 Dec;68(12):1921-1934. doi: 10.1007/s00262-019-02416-7. Epub 2019 Oct 22.
2
A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.帕博利珠单抗联合放化疗作为间变性甲状腺癌初始治疗的 II 期研究。
Thyroid. 2019 Nov;29(11):1615-1622. doi: 10.1089/thy.2019.0086.
3
Increased cytoplasmatic expression of cancer immune surveillance receptor CD1d in anaplastic thyroid carcinomas.在间变性甲状腺癌中，癌症免疫监视受体 CD1d 的细胞质表达增加。
Cancer Med. 2019 Nov;8(16):7065-7073. doi: 10.1002/cam4.2573. Epub 2019 Sep 27.
4
Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.针对晚期甲状腺癌治疗的靶向 ICAM-1 的 CAR T 细胞的制造和临床前验证。
Sci Rep. 2019 Jul 23;9(1):10634. doi: 10.1038/s41598-019-46938-7.
5
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.甲状腺癌的靶向治疗：激酶抑制剂及其他。
Endocr Rev. 2019 Dec 1;40(6):1573-1604. doi: 10.1210/er.2019-00007.
6
Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.靶向甲状腺未分化癌中的 CD47 可增强巨噬细胞对肿瘤的吞噬作用，是一种很有前途的治疗策略。
Thyroid. 2019 Jul;29(7):979-992. doi: 10.1089/thy.2018.0555. Epub 2019 May 10.
7
Targeting Tumor-Associated Macrophages in Cancer.靶向肿瘤相关巨噬细胞治疗癌症。
Trends Immunol. 2019 Apr;40(4):310-327. doi: 10.1016/j.it.2019.02.003. Epub 2019 Mar 17.
8
Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.嵌合抗原受体 T 细胞疗法和其他恶性肿瘤治疗方法：联合与机遇。
Int Immunopharmacol. 2019 May;70:498-503. doi: 10.1016/j.intimp.2019.01.010. Epub 2019 Mar 13.
9
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.抗体药物偶联物治疗药物：科学现状。
J Natl Cancer Inst. 2019 Jun 1;111(6):538-549. doi: 10.1093/jnci/djz035.
10
LSECtin on tumor-associated macrophages enhances breast cancer stemness via interaction with its receptor BTN3A3.肿瘤相关巨噬细胞上的 LSECtin 通过与其受体 BTN3A3 的相互作用增强乳腺癌干细胞特性。
Cell Res. 2019 May;29(5):365-378. doi: 10.1038/s41422-019-0155-6. Epub 2019 Mar 11.
Zotero 插件